Drug · Small Molecule

Chlorambucil

CI-DRUG-00000155Explore in graph →NCIt C362 CHEMBL515 CIViC Approved

Regulatory

Approvals (2)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

health-canada-dpdRegulatory1 approval record · authority, jurisdiction and indication text as published.

Jurisdiction · authority	Cancer	Indication	Status	Approval date	Source
CA Health Canada	—	Marketed in Canada as LEUKERAN (DIN 00004626) under ATC L01AA02 CHLORAMBUCIL. Indications are not published in the Drug Product Database — see the Health Canada Product Monograph.	approvedsource: Marketed	Dec 31, 1957	health-canada-dpd

Health Canada records are DIN-level: one row per marketed product (brand, strength, form). The Drug Product Database does not publish indications, so no cancer is stated for these rows, and a cancelled or dormant DIN is the status of that one product — not a withdrawal of the molecule.

Data updated 2 days agoSource updated unknown

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Scope	Stage	Max phase	Active	Recruiting	Phase 3	Trials	Approvals	Jurisdictions	First approval	First trial
All cancers	Approved	Phase 4	6	1	30	46	2	CA, US	Mar 18, 1957	1993-11
Leukemia	Phase4	Phase 4	4	0	21	32	0	—	—	1999-10
Non-Hodgkin Lymphoma	Phase3	Phase 3	2	0	5	8	0	—	—	2001-06
Malignant Gastric Neoplasm	Phase3	Phase 3	0	0	1	1	0	—	—

Curated evidence

Clinical evidence (1)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–1 of 1 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
FANCC Loss-of-function1
Chlorambucil + Cisplatin

Clinical trials

Trials with this intervention (47)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–47 of 47 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03462719	A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(GLOW)	active not recruiting	Phase 3	211	Janssen Research & Development, LLCINDUSTRY	14	Sep 28, 2026	clinicaltrials
NCT04075292	Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia

Molecule

Record

Kind: Small Molecule
Mechanism: DNA inhibitor
UNII: 18D0SL7309
Aliases: 4-[Bis(2-chloroethyl)amino]benzenebutanoic Acid, 4-[p-[Bis(2-chloroethyl)amino]phenyl]butyric Acid, Alti-chlorambucil, Ambochlorin, Amboclorin, Aminochlorambucil, Benzenebutanoic Acid, 4-[bis(2-chloroethyl)amino]- (9CI), Butyric Acid, 4-(p-[bis(2-chloroethyl)amino]phenyl)-, Butyric Acid, 4-(p-bis(2-chloroethyl)aminophenyl), CB 1348, CB-1348, CHL, Chlorambucil, Chlorambucilum, Chloraminophen, Chloraminophene, Chlorbutin, Chlorbutine, Chlorbutinum, Chloroambucil, Chlorobutin, Chlorobutine, Clorambucilo, Ecloril, Elcoril, .gamma.-(p-bis(2-chloroethyl)aminophenyl)butyric Acid, .gamma.-[p-Di(2-chloroethyl)aminophenyl]butyric Acid, Leukeran, LEUKERAN, Leukersan … (+11)

Data updated 21 minutes agoSource updated unknown

Identifiers

Codes (3)

Upstream identifiers kept as first-class codes; each links to its registry where a stable public URL exists.

System	Code	Label
ATC (WHO)	L01AA02	CHLORAMBUCIL
DIN (Health Canada)	00004626